Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
31
05
2021
accepted:
03
02
2022
revised:
06
04
2022
pubmed:
26
3
2022
medline:
9
4
2022
entrez:
25
3
2022
Statut:
epublish
Résumé
Rift Valley fever (RVF) is an emerging, neglected, mosquito-borne viral zoonosis associated with significant morbidity, mortality and expanding geographical scope. The clinical signs and symptoms in humans are non-specific and case definitions vary. We reviewed and analysed the clinical manifestations of RVF in humans. In this systematic review and meta-analysis we searched on different dates, the Embase (from 1947 to 13th October 2019), Medline (1946 to 14th October 2019), Global Health (1910 to 15th October 2019), and Web of Science (1970 to 15th October 2019) databases. Studies published in English, reporting frequency of symptoms in humans, and laboratory confirmed RVF were included. Animal studies, studies among asymptomatic volunteers, and single case reports for which a proportion could not be estimated, were excluded. Quality assessment was done using a modified Hoy and Brooks et al tool, data was extracted, and pooled frequency estimates calculated using random effects meta-analysis. Of the 3765 articles retrieved, less than 1% (32 articles) were included in the systematic review and meta-analysis. Nine RVF clinical syndromes were reported including the general febrile, renal, gastrointestinal, hepatic, haemorrhagic, visual, neurological, cardio-pulmonary, and obstetric syndromes. The most common clinical manifestations included fever (81%; 95% Confidence Interval (CI) 69-91; [26 studies, 1286 patients]), renal failure (41%; 23-59; [4, 327]), nausea (38%; 12-67; [6, 325]), jaundice (26%; 16-36; [15, 393]), haemorrhagic disease (26%; 17-36; [16, 277]), partial blindness (24%; 7-45; [11, 225]), encephalitis (21%; 11-33; [4, 327]), cough (4%; 0-17; [4, 11]), and miscarriage (54%) respectively. Death occurred in 21% (95% CI 14-29; [16 studies, 328 patients]) of cases, most of whom were hospitalised. This study delineates the complex symptomatology of human RVF disease into syndromes. This approach is likely to improve case definitions and detection rates, impact outbreak control, increase public awareness about RVF, and subsequently inform 'one-health' policies. This study provides a pooled estimate of the proportion of RVF clinical manifestations alongside a narrative description of clinical syndromes. However, most studies reviewed were case series with small sample sizes and enrolled mostly in-patients and out-patients, and captured symptoms either sparsely or using broad category terms.
Sections du résumé
BACKGROUND
Rift Valley fever (RVF) is an emerging, neglected, mosquito-borne viral zoonosis associated with significant morbidity, mortality and expanding geographical scope. The clinical signs and symptoms in humans are non-specific and case definitions vary. We reviewed and analysed the clinical manifestations of RVF in humans.
METHODS
In this systematic review and meta-analysis we searched on different dates, the Embase (from 1947 to 13th October 2019), Medline (1946 to 14th October 2019), Global Health (1910 to 15th October 2019), and Web of Science (1970 to 15th October 2019) databases. Studies published in English, reporting frequency of symptoms in humans, and laboratory confirmed RVF were included. Animal studies, studies among asymptomatic volunteers, and single case reports for which a proportion could not be estimated, were excluded. Quality assessment was done using a modified Hoy and Brooks et al tool, data was extracted, and pooled frequency estimates calculated using random effects meta-analysis.
RESULTS
Of the 3765 articles retrieved, less than 1% (32 articles) were included in the systematic review and meta-analysis. Nine RVF clinical syndromes were reported including the general febrile, renal, gastrointestinal, hepatic, haemorrhagic, visual, neurological, cardio-pulmonary, and obstetric syndromes. The most common clinical manifestations included fever (81%; 95% Confidence Interval (CI) 69-91; [26 studies, 1286 patients]), renal failure (41%; 23-59; [4, 327]), nausea (38%; 12-67; [6, 325]), jaundice (26%; 16-36; [15, 393]), haemorrhagic disease (26%; 17-36; [16, 277]), partial blindness (24%; 7-45; [11, 225]), encephalitis (21%; 11-33; [4, 327]), cough (4%; 0-17; [4, 11]), and miscarriage (54%) respectively. Death occurred in 21% (95% CI 14-29; [16 studies, 328 patients]) of cases, most of whom were hospitalised.
DISCUSSION
This study delineates the complex symptomatology of human RVF disease into syndromes. This approach is likely to improve case definitions and detection rates, impact outbreak control, increase public awareness about RVF, and subsequently inform 'one-health' policies. This study provides a pooled estimate of the proportion of RVF clinical manifestations alongside a narrative description of clinical syndromes. However, most studies reviewed were case series with small sample sizes and enrolled mostly in-patients and out-patients, and captured symptoms either sparsely or using broad category terms.
Identifiants
pubmed: 35333856
doi: 10.1371/journal.pntd.0010233
pii: PNTD-D-21-00768
pmc: PMC8986116
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0010233Subventions
Organisme : Medical Research Council
ID : 16/107/02
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00027/5
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203077_Z_16_Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Onderstepoort J Vet Res. 2002 Mar;69(1):95-8
pubmed: 12092782
Am J Clin Pathol. 2014 Jun;141(6):791-5
pubmed: 24838322
S Afr Med J. 1951 Nov 3;25(44):797-800
pubmed: 14892917
Vaccine. 2015 Oct 13;33(42):5520-5531
pubmed: 26296499
Arch Virol. 1988;99(1-2):31-44
pubmed: 3355374
Curr Opin Infect Dis. 2015 Feb;28(1):83-5
pubmed: 25501666
Emerg Infect Dis. 2007 Jul;13(7):1016-23
pubmed: 18214173
PLoS Negl Trop Dis. 2018 May 4;12(5):e0006460
pubmed: 29727450
Viruses. 2011 May;3(5):493-519
pubmed: 21666766
S Afr Med J. 1951 Dec 1;25(48):890-1
pubmed: 14892941
Open Forum Infect Dis. 2016 Sep 27;3(4):ofw200
pubmed: 27844026
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):14-21
pubmed: 20682901
MMWR Morb Mortal Wkly Rep. 2016 Nov 04;65(43):1200-1201
pubmed: 27811840
PLoS Negl Trop Dis. 2020 Jan 21;14(1):e0007898
pubmed: 31961862
Saudi J Kidney Dis Transpl. 2009 Nov;20(6):1047-52
pubmed: 19861868
Ann N Y Acad Sci. 2006 Oct;1081:240-2
pubmed: 17135517
Immunobiology. 2007;212(6):475-90
pubmed: 17544832
Emerg Microbes Infect. 2017 Jan 18;6(1):e4
pubmed: 28096531
Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):377-83
pubmed: 20610980
Euro Surveill. 2016 May 5;21(18):
pubmed: 27172608
Emerg Infect Dis. 2003 Oct;9(10):1197-204
pubmed: 14609452
J Trop Med Hyg. 1994 Aug;97(4):228-30
pubmed: 8064945
Trans R Soc Trop Med Hyg. 1978;72(4):392-6
pubmed: 568328
S Afr Med J. 1951 Dec 15;25(50):926-30
pubmed: 14892952
Ann Trop Med Parasitol. 1950 Jul;44(2):132-45
pubmed: 24537996
Trop Med Int Health. 1999 Feb;4(2):114-9
pubmed: 10206265
Virol J. 2015 Oct 06;12:159
pubmed: 26437779
Community Genet. 2007;10(4):201-17
pubmed: 17895626
Ann Trop Med Parasitol. 1972 Sep;66(3):343-55
pubmed: 4404504
Proc Soc Exp Biol Med. 1947 Apr;64(4):385-9
pubmed: 20239431
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
Cent Afr J Med. 1980 Jun;26(6):122-6
pubmed: 7190877
Lancet Glob Health. 2016 Nov;4(11):e864-e871
pubmed: 27692776
Emerg Microbes Infect. 2013 Dec;2(12):e81
pubmed: 26038446
PLoS Negl Trop Dis. 2013 Apr 04;7(4):e2156
pubmed: 23593523
S Afr Med J. 1977 Jun 11;51(24):867-71
pubmed: 561445
J Immunol. 1949 Jun;62(2):213-27
pubmed: 18153372
J Virol. 1999 Jun;73(6):5018-25
pubmed: 10233964
Infect Ecol Epidemiol. 2015 Jul 31;5:28024
pubmed: 26234531
Vet Med Sci. 2019 Feb;5(1):70-78
pubmed: 30411868
Ann Trop Paediatr. 2006 Sep;26(3):251-3
pubmed: 16925964
Onderstepoort J Vet Res. 1977 Jun;44(2):119-26
pubmed: 351506
Am J Trop Med Hyg. 2013 Sep;89(3):495-7
pubmed: 23918215
Sci Adv. 2018 Dec 05;4(12):eaau9812
pubmed: 30525107
Ann Inst Pasteur Virol. 1988 Jul-Sep;139(3):301-4
pubmed: 2905142
J Exp Med. 1935 Aug 31;62(3):433-48
pubmed: 19870425
Open Forum Infect Dis. 2016 Jul 21;3(3):ofw149
pubmed: 27704007
Clin Infect Dis. 2003 Oct 15;37(8):1084-92
pubmed: 14523773
PLoS Negl Trop Dis. 2021 Aug 19;15(8):e0009626
pubmed: 34411097
Br J Ophthalmol. 1980 May;64(5):366-74
pubmed: 7192158
Am J Trop Med Hyg. 2010 Mar;82(3):371-5
pubmed: 20207858
Am J Trop Med Hyg. 1995 Oct;53(4):405-11
pubmed: 7485695
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
PLoS Negl Trop Dis. 2015 Mar 10;9(3):e0003584
pubmed: 25756647
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):5-13
pubmed: 20682900
Ann Clin Microbiol Antimicrob. 2020 Jan 22;19(1):4
pubmed: 31969141
J Hyg (Lond). 1964 Jun;62:239-56
pubmed: 14171274
J Am Med Inform Assoc. 2004 Mar-Apr;11(2):141-50
pubmed: 14633933
Int J Infect Dis. 2010 Feb;14(2):e179-80
pubmed: 19570703
Emerg Infect Dis. 2014 Feb;20(2):296-9
pubmed: 24447334
Trans R Soc Trop Med Hyg. 1979;73(6):630-3
pubmed: 575446
Clin Infect Dis. 2003 Feb 1;36(3):245-52
pubmed: 12539063
Euro Surveill. 2010 Mar 11;15(10):19506
pubmed: 20403309
S Afr Med J. 2011 Apr;101(4):263-6
pubmed: 21786732
J Infect Dis. 2018 Oct 20;218(11):1847-1851
pubmed: 29955891
Curr Opin Infect Dis. 2018 Feb;31(1):39-44
pubmed: 29176348
J Am Vet Med Assoc. 2009 Apr 1;234(7):883-93
pubmed: 19335238
Prev Vet Med. 2007 Nov 15;82(1-2):72-82
pubmed: 17570545
J Virol. 2007 Mar;81(6):2805-16
pubmed: 17192303
BMJ Open. 2016 Jul 12;6(7):e010247
pubmed: 27406637
Trends Parasitol. 2008 Jun;24(6):243-5
pubmed: 18450514
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Rev Sci Tech. 2004 Aug;23(2):613-23
pubmed: 15702723
Vet Res. 2010 Nov-Dec;41(6):61
pubmed: 21188836
Emerg Microbes Infect. 2016 Jun 22;5:e58
pubmed: 27329846
Br J Exp Pathol. 1956 Apr;37(2):99-109
pubmed: 13315885
Cent Afr J Med. 1979 Jan;25(1):1-8
pubmed: 421262
Vet Ital. 2006 Jan-Mar;42(1):31-53
pubmed: 20429078
Lancet Infect Dis. 2005 Mar;5(3):156-64
pubmed: 15766650
PLoS Negl Trop Dis. 2018 Jul 23;12(7):e0006627
pubmed: 30036382
Ophthalmology. 2005 Feb;112(2):313-8
pubmed: 15691569
J Infect Dis. 2011 Mar 1;203(5):655-65
pubmed: 21282193
Cell Host Microbe. 2012 Oct 18;12(4):458-69
pubmed: 23084915
Ann Inst Pasteur Virol. 1988 Jul-Sep;139(3):307-8
pubmed: 3207509
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):22-7
pubmed: 20682902
J Virol. 2010 Jan;84(2):928-39
pubmed: 19889787
J Med Virol. 2008 May;80(5):929
pubmed: 18360907